[1]
Kogawa, A.C.; Salgado, H.R.N. Impurities and forced degradation studies: A review. Curr. Pharm. Anal., 2016, 12, 18-24.
[2]
Holm, R.; Elder, D.P. Analytical advances in pharmaceutical impurity profiling. Eur. J. Pharm. Sci., 2016, 87(118), 1-89.
[3]
Luo, Z.; Liu, A.; Liu, Y.; Wang, G.; Chen, X.; Wang, H.; Li, M.; Zhang, H.; Qiu, Y.; Zhai, H. Development of a stability- indicating hplc method for simultaneous determination of ten related substances in vonoprazan fumarate drug substance. J. Pharm. Biomed. Anal., 2018, 149, 133-142.
[4]
Jain, D.; Basniwal, P.K. Forced degradation and impurity profiling: recent trends in analytical perspectives. J. Pharm. Biomed. Anal., 2013, 86(13), 11-35.
[5]
Blessy, M.; Patel, R.D.; Prajapati, P.N.; Agrawal, Y.K. Development of forced degradation and stability indicating studies of drugs - a review. J. Pharm. Anal., 2014, 4(3), 159-165.
[6]
Messerli, F.H.; Makani, H.; Benjo, A.; Romero, J.; Alviar, C.; Bangalore, S. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J. Am. Coll. Cardiol., 2011, 57(5), 590-600.
[7]
Pires, M.A.S.; Dos Santos, R.A.S.; Sinisterra, R.D. Pharmaceutical composition of hydrochlorothiazide: β-Cyclodextrin: preparation by three different methods, physico-chemical characterization and in vivo diuretic activity evaluation. Molecules, 2011, 16(6), 4482-4499.
[8]
Santoveña, A.; Hernández-Paiz, Z.; Fariña, J.B. Design of a pediatric oral formulation with a low proportion of hydrochlorothiazide. Int. J. Pharm., 2012, 423(2), 360-364.
[9]
Fang, X.; Bibart, R.T.; Mayr, S.; Yin, W.; Harmon, P.A.; Mccafferty, J.F.; Tyrrell, R.J.; Reed, R.A. Purification and identifcation of an impurity in bulk hydrochlorothiazide. J. Pharm. Sci., 2001, 90(11), 1800-1809.
[10]
Tagliari, M.P.; Stulzer, H.K.; Murakami, F.S.; Kuminek, G.; Valente, B.; Oliveira, P.R.; Segatto Silva, M.A. Development and validation of a stability-indicating lc method to quantify hydrochlorothiazide in oral suspension for pediatric use. Chromatographia, 2008, 67(7-8), 647-652.
[11]
Sangoi, M.S.; Wrasse-Sangoi, M.; Oliveira, P.R.; Rolim, C.M.B.; Steppe, M. Simultaneous determination of aliskiren and hydrochlorothiazide from their pharmaceutical preparations using a validated stability-indicating MEKC method. J. Sep. Sci., 2011, 34(15), 1859-1866.
[12]
Mollica, J.A.; Rehm, C.R.; Smith, J.B. Hydrolysis of Hydrochlorothiazide. J. Pharm. Sci., 1969, 58(5), 635-636.
[13]
Lusina, M.; Cindrić, T.; Tomaić, J.; Peko, M.; Pozaić, L.; Musulin, N. Stability study of losartan/hydrochlorothiazide tablets. Int. J. Pharm., 2005, 291(1-2), 127-137.
[14]
Daniels, S.L.; Vanderwielen, A.J. Stability‐indicating Assay for Hydrochlorothiazide. J. Pharm. Sci., 1981, 70(2), 211-215.
[15]
Thomas, B.R.; Fang, X.G.; Chen, X.; Tyrrell, R.J.; Ghodbane, S. Validated micellar electrokinetic capillary chromatography method for quality control of the drug substances hydrochlorothiazide and chlorothiazide. J. Chromatogr. B., 1994, 657(2), 383-394.
[16]
Mahajan, A.A.; Thaker, A.K.; Mohanraj, K.LC. LC-MS/MS studies for the identification and characterization of degradation products of hydrochlorothiazide and establishment of mechanistic approach towards degradation. J. Braz. Chem. Soc., 2012, 23(3), 445-452.
[17]
Urupina, D.; Al-Bazi, S. Stability-indicating method development and validation for the assay of hydrochlorothiazide and determination of impurities/ degradants in hydrochlorothiazide raw material and tablets using reverse-phase liquid chromatography. Austin J. Anal. Pharm. Chem., 2016, 3(3), 1-7.
[18]
International Conference on Harmonisation Guideline on
Photostability Testing of New Drug Substances and Products, Q1B; 1996.
[19]
International Conference on Harmonisation Guideline on Stability
Testing of New Drug Substances and Products, Q1A(R2); 2003.
[20]
International Conference on Harmonisation Guideline on
Validation of Analytical Procedures: Text and Methodology,
Q2(R1); 2005.
[21]
International Conference on Harmonisation Guideline on
Impurities in New Drug Products, Q3B(R2); 2006.
[22]
Hertzog, D.L.; McCafferty, J.F.; Fang, X.; Tyrrell, R.J.; Reed, R.A. Development and validation of a stability-indicating hplc method for the simultaneous determination of losartan potassium, hydrochlorothiazide, and their degradation products. J. Pharm. Biomed. Anal., 2002, 30(3), 747-760.
[23]
Deventer, K.; Baele, G.; Van Eenoo, P.; Pozo, O.J.; Delbeke, F.T. Stability of selected chlorinated thiazide diuretics. J. Pharm. Biomed. Anal., 2009, 49(2), 519-524.
[24]
Razak, O.A. Electrochemical study of hydrochlorothiazide and its determination in urine and tablets. J. Pharm. Biomed. Anal., 2004, 34(2), 433-440.
[25]
Mendes, C.; Buttchevitz, A.; Kruger, J.H.; Kratz, J.M.; Simões, C.M.O.; De Oliveira Benedet, P.; Oliveira, P.R.; Silva, M.A.S. Inclusion complexes of hydrochlorothiazide and β-cyclodextrin: physicochemical characteristics, in vitro and in vivo studies. Eur. J. Pharm. Sci., 2016, 83, 71-78.